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Abstract
Background: Nonadherence to prescribed regimens for opioid analgesic agents contributes to increasing opioid abuse and
overdose death. Opioids are frequently prescribed on an as-needed basis, placing the responsibility to determine opioid dose and
frequency with the patient. There is wide variability in physician prescribing patterns because of the lack of data describing how
patients actually use as-needed opioid analgesics. Digital pill systems have a radiofrequency emitter that directly measures
medication ingestion events, and they provide an opportunity to discover the dose, timing, and duration of opioid therapy.
Objective: The purpose of this study was to determine the feasibility of a novel digital pill system to measure as-needed opioid
ingestion patterns in patients discharged from the emergency department (ED) after an acute bony fracture.
Methods: We used a digital pill with individuals who presented to a teaching hospital ED with an acute extremity fracture. The
digital pill consisted of a digital radiofrequency emitter within a standard gelatin capsule that encapsulated an oxycodone tablet.
When ingested, the gastric chloride ion gradient activated the digital pill, transmitting a radiofrequency signal that was received
by a hip-worn receiver, which then transmitted the ingestion data to a cloud-based server. After a brief, hands-on training session
in the ED, study participants were discharged home and used the digital pill system to ingest oxycodone prescribed as needed for
pain for one week. We conducted pill counts to verify digital pill data and open-ended interviews with participants at their
follow-up appointment with orthopedics or at one week after enrollment in the study to determine the knowledge, attitudes, beliefs,
and practices regarding digital pills. We analyzed open-ended interviews using applied thematic analysis.
Results: We recruited 10 study participants and recorded 96 ingestion events (87.3%, 96/110 accuracy). Study participants
reported being able to operate all aspects of the digital pill system after their training. Two participants stopped using the digital
pill, reporting they were in too much pain to focus on the novel technology. The digital pill system detected multiple simultaneous
ingestion events by the digital pill system. Participants ingested a mean 8 (SD 5) digital pills during the study period and four
participants continued on opioids at the end of the study period. After interacting with the digital pill system in the real world,
participants found the system highly acceptable (80%, 8/10) and reported a willingness to continue to use a digital pill to improve
medication adherence monitoring (90%, 9/10).
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Conclusions: The digital pill is a feasible method to measure real-time opioid ingestion patterns in individuals with acute pain
and to develop real-time interventions if opioid abuse is detected. Deploying digital pills is possible through the ED with a short
instructional course. Patients who used the digital pill accepted the technology.
(J Med Internet Res 2017;19(1):e19)   doi:10.2196/jmir.7050
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Introduction
Deaths from opioid overdose in the United States have paralleled
a rise in the number of opioid analgesic medications being
prescribed [1]. In 2014, more than 259 million prescriptions for
opioids were dispensed to the American public [1-3]. Opioids
are commonly prescribed on an as-needed basis, meaning that
decisions regarding opioid dose and frequency are left up to
patients. Unfortunately, the ways in which patients use as-needed
opioids outside of hospital settings are unknown, as is the
optimal duration of opioid therapy needed for acutely painful
conditions. This uncertainty has contributed to wide variability
in opioid-prescribing patterns, often for an excessive number
of opioid pills than what are actually needed [2,4-6].
Determining adherence to a prescribed opioid medication
regimen after discharge and measuring the ways in which
patients ingest as-needed medications pose methodological
challenges. Because patients determine opioid ingestion dose
and frequency based on temporal perception of pain, common
measures of adherence (eg, smart pill bottles, pharmacy refill
histories, or patient diaries) are impractical or provide aggregate
measures that cannot delineate temporal patterns of opioid
ingestion [7]. These traditional models measure adherence
indirectly and are fraught with recall bias, measure ingestions
in aggregate, and are easy to subvert (eg, opening the bottle
once, but taking out several pills) [7,8]. Precise measures of
opioid ingestion patterns are important because they can suggest
incomplete treatment of pain, the development of tolerance, or
the transition into problematic use [9].
A Novel Digital Pill System to Measure Medication
Ingestion Patterns
Digital pills that activate upon contact with the stomach provide
a reliable method to directly measure, rather than infer, opioid
ingestion patterns in real time [10,11]. Digital pills consist of a
gelatin capsule containing a digital radiofrequency emitter
compounded with the desired medication (Figure 1) [10,12].
When ingested, the radiofrequency emitter is activated by the
chloride ion gradient in the stomach to transmit a unique signal.
A hip-worn receiver detects this signal before relaying data
regarding the identity of the ingested medication and time of
ingestion through third-generation (3G) cellular signaling to a
cloud-based server compliant with Health Information
Technology for Economic and Clinical Health (HITECH) and
the Health Insurance Portability and Accountability Act
(HIPAA). A locus for communication, the server can notify
clinicians about the ingestion, send messages that can include
behavioral interventions to the patient, and facilitate
communication between clinician and patient. Digital pills are
energized by the specific chloride ion gradient in the stomach
and, therefore, cannot be activated outside of the body. Because
each digital pill emits a unique frequency, the system can record
multiple simultaneous ingestion events. This technological
advantage, which allows the direct observation of the number
of opioid pills a patient ingests as well as the time period
between opioid ingestion, can personalize the number of opioid
pills and the duration of as-needed opioid therapy [12]. Digital
pills are simple to operate and passively measure adherence,
decreasing the need for an individual to interact with technology
to transmit adherence data. Unfortunately, the usability and
acceptability of digital pills among “real-world” patient
populations remains unknown. Accordingly, we sought to
determine the acceptability of digital pills to emergency
department (ED) patients with acute extremity fractures
instructed to ingest oxycodone prescribed on an as-needed basis.
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Figure 1. An ingestible radiofrequency sensor is incorporated into a gelatin capsule (A), which is compounded with the desired medication (B) to create
a digital pill (C). Once the digital pill is ingested (1), it is activated and transmits a radiofrequency signal to a hip worn device (2) that collects and
transmits ingestion data to a cloud-based server driving an interface (3) that displays ingestion data to clinicians and patients.
Methods
Our study was based at a large tertiary care academic ED, and
approved by its institutional review board (University of
Massachusetts Medical School, Worcester, MA, USA). We
used a digital pill (eTectRx, Newbury, FL, USA) compounded
with oxycodone tablets in patients who presented to the ED
after suffering an acute extremity fracture to measure real-world
ingestion patterns in these patients. Digital pills were purchased
directly from the manufacturer (eTectRx) and compounded with
5 mg oxycodone tablets using a standard capsule-filling machine
by our hospital investigational drug services pharmacy.
Compounded digital pills were dispensed in blister packages.
We considered alternative digital pill systems that used
radiofrequency signaling to detect ingestion events. Other digital
pills required the radiofrequency emitter to be adhered onto a
placebo pill, thus requiring ingestion of the study medication
and placebo pill to record an ingestion event. We elected to
utilize the eTectRx system because it offered the opportunity
to directly measure, rather than infer, medication ingestion.
Recruitment
A convenience sample of ED patients was recruited during
daytime hours when research staff was available. Patients were
eligible for the study if they were consenting adults (>18 years);
presenting to the ED after an isolated acute fracture; had no
history of psychiatric illness, substance abuse disorder, or
chronic opioid use (prescribed opioids for more than one week
in duration); and were planned to be discharged with opioid
analgesics. Patients who met the eligibility criteria were
approached by study staff. A chart review was conducted to
ensure potential study participants did not meet exclusion
criteria. Basic demographic information including age, gender,
and ED pain scale were collected. Study staff then briefed
potential participants on the purpose of the study and potential
study participants were shown components of the digital pill.
Participants who agreed to participate in the study provided
written informed consent. Participants were compensated US
$100 for participation in the study.
Training to Use the Digital Pill
Study staff provided participants with hands-on training lasting
approximately 20 minutes on the operation of the digital pill.
Training included a demonstration of digital pill operations,
explanation of all the hardware components, and registration
of the study participant on the cloud interface. Participants were
counseled by the study staff to use nonopioid analgesics
(nonsteroidal anti-inflammatory agents or acetaminophen) to
manage their pain, and use oxycodone-containing digital pills
as needed for episodes of pain not controlled with other
medications. Participants then ingested an oxycodone-containing
digital pill under observation by study staff to demonstrate their
understanding of the system and to verify that all components
of the system were operational. If a patient reported their pain
levels were managed during the time of system training,
participants demonstrated their understanding of the system
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without ingesting an oxycodone pill. On discharge, participants
received a prescription for one-to-two digital pills containing 5
mg oxycodone every 8 hours as needed for pain (total of 21
digital pills) in addition to a hip-worn device to capture ingestion
data. Study participants enrolled in the study did not receive
additional opioid analgesics from the primary team.
Qualitative Analysis and Verification of Ingestion
Participants returned to the hospital’s clinical research center
at the time of their orthopedic follow-up appointment or at one
week after ED discharge to return the digital pill system and
any uningested oxycodone digital pills. Equipment return and
appointments were arranged with the study participants by study
staff. We validated ingestion data from the digital pill using pill
counts; we resolved discrepancies, if present, with the
participant.
Investigators (PRC, EWB, BI) conducted brief (approximately
15 minutes), open-ended interviews with each study participant.
We used an interview guide to ensure that each participant was
asked the same questions; questions centered on acceptance of
the digital pill, barriers to use, adequacy of pain control, and
potential improvements in the system. We adapted the technique
of applied thematic analysis to code interviews in the context
of this pilot study [13]. Participant responses were transcribed
by BI and reviewed by the three qualitative analysts (PRC, BI,
and EWB), who then met to review topics. Deductive codes
were created based on the key interview questions (acceptance
of digital pills, willingness to use digital pills, and data privacy);
additional inductive codes were derived from emergent
participant comments (ie, willingness to use during chronic care,
text message reminders, data security, and privacy). After
coding, two of the investigators (PRC and BI) met and compared
codes to ensure interrater reliability. Summaries of key codes
were written and reviewed among the investigators. In this
limited and exploratory sample, a key concern was to capture
both the common and uncommon experiences participants
reported with the pill and sensor.
Results
Eighteen individuals met the inclusion criteria for the study and
were approached by the study team (Figure 2). Ten individuals
ultimately consented and enrolled in the study (Table 1). They
were evenly split between men and women and ranged in age
from 21 to 63 years, with a mean age of 43 (SD 15) years. All
participants successfully completed training in the ED and used
the digital pill system at home. All individuals reported severe
pain (pain scale ≥7) on initial presentation to the ED. Five
participants required delayed surgical management of their
fracture and five participants were managed nonoperatively.
Participants ingested a mean 48 (SD 24) mg oxycodone during
the course of the study (Table 2). Oxycodone was ingested in
greater frequency during the first 24 hours after discharge, with
declining use by 72 hours. Seven participants de-escalated their
oxycodone use over two days, changing dosing frequency (from
every 4-6 hours to every 8-12 hours) in conjunction with dosing
amount (from 10 mg oxycodone per ingestion to 5 mg
oxycodone per ingestion). One participant experienced pain
from associated injuries and increased the oxycodone dose over
the study period. Four participants reported requiring continued
opioid analgesia at the end of the study period (40%, 4/10);
these participants all required operative repair of their fracture.
No participants with nonoperative fractures reported persistent
opioid use at the end of the study period.
Table 1. Demographics, fracture pattern, and final treatment of study participants (N=10)
Time until orthopedic
follow-up (days)
Definitive therapyInjurySexAge (years)Partici-
pant
3Surgical fixationLisfranc fractureM321
3Surgical fixationDistal radius ulna fractureF482
4Surgical fixationTrimalleolar fractureM553
3Surgical fixationBimalleolar fractureM554
8Knee immobilizerTibial plateau, proximal fibula fractureF635
20Cervical collarC6 right pedicle fracture, L2+L3 transverse
process fracture
M216
7Controlled ankle motion bootDistal fibula fractureF447
8Short leg castDistal fibula fractureF278
4Surgical fixationDistal radius fracture, ulnar-styloid fractureF219
14Thoracolumbosacral orthosisL3 superior endplate fractureM5010
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Table 2. Participant oxycodone ingestion patterns from digital pills.
Continued oxycodone for
pain after 7 days
Oxycodone dose ingested
in 7 days (mg)
Number of doses ingested per day
(pills/day)
Pain scaleParticipant
7654321ED dischargeEDa arrival
Yes754421121771
Yes600122322Not recorded92
Yesb700000473Not recorded103
Yes4500003333104
No802024422675
No502202202586
No3000021124107
No100001100Not recorded38
No400000125589
No200001111Not recorded610
aED: emergency department.
bIndividual did not record continued ingestions (days 4-7) because he stopped interacting with the digital pill.
Figure 2. Study enrollment schema.
Fidelity of the Digital Pill System
The digital pill system was able to accurately measure
oxycodone ingestion events (Table 3). Participants returned the
remaining digital pills at the conclusion of the study and a pill
count was used to verify the fidelity of the digital pill system.
A total of 96 cumulative ingestion events were recorded during
the study (87.3% accuracy). A total of 14 ingestion events were
not recorded by the digital pill system; all these ingestion events
occurred in two participants who were unwilling to interact with
the technology, stating that severe pain prevented them from
using the receiver or charging the digital pill system’s batteries.
Some ingestion events were initially not recorded on the
cloud-based server due to lack of cellular reception at the study
participant’s home. Once the receiver entered cellular service,
ingestion events automatically uploaded onto the server. In these
instances, the receiver was mailed to our industry partner
(eTectRx) to confirm all ingestion events had been uploaded.
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Table 3. Accuracy of the digital pill.
System accuracy (%)Pills taken (based on pill count)Ingestion events recordedParticipant
100%15151
100%12122
70%20143
100%994
100%16165
56%18106
100%667
100%228
100%889
100%4410
87%11096Total
Patient Response to Digital Pills
We completed open-ended interviews with all participants at
the end of the study period (Textbox 1). Participants reported
being able to easily operate the digital pill. Nine participants
responded positively to the digital pill; one patient reported it
was initially difficult for him to use the hub during the first 24
hours during episodes because of severe pain (Table 3). Attitudes
toward the digital pill were positive; 80% (8/10) of participants
reported that they would be willing to use the digital pill for
adherence monitoring in chronic disease and would be willing
to share ingestion data with physicians. Also, 90% (9/10) of
participants reported they found the digital pill palatable and
easy to swallow, considered the technology valuable, and had
no problems operating the digital pill at home. One participant
reported difficulty tolerating the size of the digital pill (a
standard size 00 capsule; 8.5 mm in diameter, 23.3 mm in length;
approximately the size of an 800 mg ibuprofen tablet), but
reported willingness to use the digital pill.
Participants did not report any concerns regarding issues of
privacy when utilizing the digital pill. Participants preferred
real-time transfer of ingestion data to their physician, especially
if their physician could use their ingestion data to intervene at
potential times of escalating use. Interestingly, participants
reported that they preferred text message-based confirmation
of ingestion events and, in the context of chronic disease, would
have liked mobile phone-based text messages reminding them
to take medications.
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Textbox 1. Feasibility of a digital pill.
Acceptance of system (9/10, 90%)
• 90% of participants reported a positive experience integrating digital pill into medication regimen
• System became part of medication routine and participants developed different techniques for system use based on individual habits
• Digital pills were easy to swallow
• Appreciated receiving text messages after taking medication when an ingestion event was recorded
• Sample of participant response:
“I thought it was easy. It helped me, because I had a routine of just take the reader off of the charger and go get the medicine”
“I like getting the (text) message, it showed me that the device was working.”
Willingness to use in chronic disease (8/10, 80%)
• Participants willing to use in coordination with health care provider for observation of medication taking behavior
• Sample of participant response:
“A prompt would be nice if it was a medication I had to take daily, because people, like myself, forget to take their medication”
“Using the system actually really helped me to realize how much (oxycodone) I was taking”
2 participants reported they would not be willing to use the system in chronic disease (see barriers to use)
Equipment failure and barriers to use (2/10, 20%)
Problem: participant 2 lost reception due to poor cell coverage, so ingestion events were not transmitted via SMS to study server
Solution: ingestion events are stored on reader automatically for manual upload to server as backup
Problem: participant 5 reported that system was hard to remember to use when in severe pain; stopped using system on day 3
Solution: focus on patient-centered improvements for ease of use in next-generation digital pill (eg, integrating reader with receiver sticker into one
easy-to-wear reader as a lanyard); use digital pill for conditions not involving severe pain
Problem: participant 5 reported improved battery life would have made system easier to use when in severe pain; participant 6 did not plug in reader
when not in use causing the reader to lose power and ingestion events were not recorded on day 1 and day 2; participant 10 reported that they would
not be willing to use system in chronic disease because of having to charge reader consistently
Solution: next-generation reader will have improved battery life and not need to be charged consistently when not in use
Discussion
We demonstrated the acceptability and usability conditions of
digital pills as a medication monitoring method among patients
with acute painful conditions. Importantly, we successfully
deployed the digital pill among ED patients; ED-based research
is unique in that it oversamples poor, indigent, homeless, and
immigrant populations [14]. Notably, acceptance of the digital
pill allowed us to measure ingestion patterns in nontraditional
research participants (ie, individuals with whom we did not
have an ongoing therapeutic relationship). Therefore, digital
pills may be a potential method to reinforce adherence to short
regimens of high-risk medications such as opioids prescribed
in the ED. Furthermore, we successfully recruited and retained
participants of low socioeconomic status (including homeless
individuals); we feel that our confidence in deploying digital
pills in “real-world” environments is justified.
Our data show that digital pills can detect not only real-time
oxycodone ingestion in real-world patients, but also the patterns
by which they take these medications. Our ability to reliably
measure medication ingestion events using the digital pill arises
from the technology’s capacity to detect simultaneous ingestion
of two separate digital pills. When two simultaneous digital
pills were ingested, the digital pill recognized two distinct
ingestion events 100% of the time. These pilot data demonstrate
that digital pills can mirror an individual’s medication ingestion
pattern in the real world and that these data can be delivered to
physicians in real time.
Failure of the digital pill to record ingestion events resulted
from technical difficulties of the emerging technology (eg,
reader was not charged or lack of cellular signal at the reader
location), not operator error. Notably, in cases when the reader
could not link to a cellular network, the reader recorded
ingestion events in its on-board memory, which we downloaded
at participant follow-up. The 20 minutes of hands-on
instruction—a time period expected to drop as technology
improves—ensured fidelity to tasks needed to operate the digital
pill. This short training period and 90% acceptance of the system
implies that it is simple and intuitive for the user. We believe
technical improvements in the reader—improved battery life,
the ability to switch between wireless networks, low energy
Bluetooth and cellular transmission, and improved capture of
the radiofrequency signal—will only improve detection accuracy
and decrease the steps required to operate the reader.
We identified conflicting responses regarding the impact of a
medication monitoring system on participant behavior. For
example, participants did not perceive that physician notification
of real-time ingestion events altered their decisions surrounding
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medication use or altered the dose or frequency with which they
ingested digital pills. Conversely, in the theoretical case of
medication monitoring for chronic disease, participants reported
that the technology would be an adherence-improving measure
in itself.
Importantly, our formative interviews of study participants
demonstrate their perception that the digital pill maintains patient
privacy. This finding contrasts with multiple reports in the lay
media hypothesizing that real-time detection of medication
ingestion events could violate privacy [15,16]. Our study
participants reported that our security measures—encryption of
data streams, deidentification of ingestion data prior to
transmission, and access of data that was limited to
clinicians—were acceptable. This suggests that individuals with
other stigmatized conditions that require strict medication
adherence, such as substance abuse disorders or human
immunodeficiency virus (HIV), may also similarly accept the
data security offered through the digital pill. Continued data
security and protection of patient privacy can be accomplished
through excluding protected health information from ingestion
data (eg, transmitting only ingestion time and pill number instead
of transmitting a patient identifier) and improvements in
radiofrequency encryption.
Discovering the ways in which patients take opioids in natural
environments is of particular interest given the increasing rate
of opioid overdose deaths. Ingestion data from our study shows
that patients may require only brief periods of opioid analgesia
following an acute extremity fracture. Most study participants
ingested opioids for only 72 hours after their injury while
self-tapering their dose. Study participants experienced greatest
pain in the first 48 hours following injury. Participants
successfully controlled subsequent episodes of pain with
nonopioid analgesics such as acetaminophen or ibuprofen. Study
participants who ingested opioids after 72 hours reported doing
so for specific reasons, such as treating a second painful
condition (eg, a soft tissue laceration in one case) or to maximize
analgesia before bedtime. This formative data, although drawn
from a small cohort of patients, may provide guidance for
physicians hoping to provide effective yet safe duration of opioid
therapy.
This study represents the first time digital pills have been
deployed from the ED. We demonstrate that digital pills feasibly
monitor medication ingestion events in the real world, require
minimal training, and are acceptable by users, even those of
low socioeconomic status. Our approach may be adapted to the
deployment of digital pills to monitor chronic medication
adherence in chronic conditions such as antiretroviral agents to
prevent or treat HIV infection, or the use of anticoagulants in
atrial fibrillation. Continued advances in radiofrequency
signaling and energy harvesting will boost signal strength for
future digital pills while continued miniaturization, improved
battery life, and advanced detection techniques will allow future
receivers to blend into the background of daily life, increasing
acceptance and fidelity of digital pills. Automated interpretation
of adherence data and integration with electronic medical records
will improve data visualization by physicians and patients and
may serve as a novel method to boost adherence. Digital pills
may be an effective method to detect real-time medication
ingestion events for many chronic, expensive, and intractable
conditions.
This study had several limitations. First, our data demonstrate
the feasibility of a digital pill to monitor medication ingestion,
but the small sample size makes it difficult to determine whether
decreased opioid usage was statistically significant. Second, we
studied patients with acute extremity fracture—a painful
condition for which opioids are commonly prescribed.
Therefore, our data should not be generalized to all painful
conditions. Future studies should focus on various painful
conditions to guide the creation of a more comprehensive set
of opioid-prescribing guidelines. Third, patients in this study
had stringent enrollment criteria, including the lack of
psychiatric illness or a history of substance abuse. Fourth, we
did not follow patients after their operative repair because our
main goal was to understand the feasibility and acceptability of
the digital pill. Therefore, we do not know the patterns of
chronic opioid use.
This pilot study demonstrates the feasibility of digital pills to
detect medication ingestion events and discern patterns of opioid
analgesic use in patients discharged from the ED. Patients
readily accept and interact with digital pills in the real world.
Our study adds to the growing data regarding natural
environment interactions with digital pills. When formulated
with oxycodone, digital pills can help clinicians discover natural
ingestion patterns of opioids.
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